SCHEMBL504122

SCHEMBL504122

O=C(O)Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RXRA P19793 10/20 0.68
RXRG P48443 10/20 0.68
RXRB P28702 9/20 0.68
PSEN1 P49768 1/20 0.53
PSEN2 P49810 1/20 0.53
APH1B Q8WW43 1/20 0.53
NCSTN Q92542 1/20 0.53
APH1A Q96BI3 1/20 0.53
PSENEN Q9NZ42 1/20 0.53
TACR1 P25103 4/20 0.51
CES2 O00748 1/20 0.50
LMNA P02545 1/20 0.49
AGBL2 Q5U5Z8 1/20 0.47
IDO1 P14902 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494395 0.88 RXRA (0.56) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL153296 0.88 RXRA (0.67) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL10153376 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL22773948 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL29467110 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL2184606 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL17147284 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL29927941 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL586184 0.87 RXRA (0.54) RXRARXRGRXRBPSEN1PSEN2
SCHEMBL6865708 0.84 CES2 (0.52) RXRARXRGRXRBTACR1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-115872857-A Netupitant key impurity and preparation method thereof 四川科伦药物研究院有限公司 2023-03-31 CN claimed
CN-115215879-A 3-aryl-4, 5-pyranocoumarin derivatives, and preparation method and application thereof 广西中医药大学 2022-10-21 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
CN-105601495-B It is a kind of how the synthetic method of the smooth intermediate of appropriate pyrrole 合肥利夫生物科技有限公司 2018-05-29 CN claimed
US-9910026-B2 High temperature tracers for downhole detection of produced water BAKER HUGHES, A GE COMPANY, LLC (US) 2018-03-06 US claimed
US-20160209391-A1 HIGH TEMPERATURE TRACERS FOR DOWNHOLE DETECTION OF PRODUCED WATER BAKER HUGHES INCORPORATED (US) 2016-07-21 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-6027890-A DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY RAPIGENE, INC. (US) 2000-02-22 US claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
US-5980585-A NONTOXIC; HAIR DYE L'OREAL (FR) 1999-11-09 US claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS RXRA 4626/4885RXRG 4564/4885RXRB 4639/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS RXRA 4626/4885RXRG 4564/4885RXRB 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.